# ATORvastatin in Pulmonary TUBerculosis

> **NCT06199921** · PHASE2 · RECRUITING · sponsor: **Obafemi Awolowo University Teaching Hospital** · enrollment: 440 (estimated)

## Conditions studied

- Pulmonary Tuberculosis
- Tuberculosis
- Koch's Disease

## Interventions

- **DRUG:** Atorvastatin 20mg
- **DRUG:** Atorvastatin 40mg
- **DRUG:** Atorvastatin 60mg
- **DRUG:** Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)

## Key facts

- **NCT ID:** NCT06199921
- **Lead sponsor:** Obafemi Awolowo University Teaching Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-03
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06199921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06199921, "ATORvastatin in Pulmonary TUBerculosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06199921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*